570 related articles for article (PubMed ID: 9741514)
41. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
Sigurdsson A; Swedberg K
Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
[TBL] [Abstract][Full Text] [Related]
42. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
Das SR; Drazner MH; Yancy CW; Stevenson LW; Gersh BJ; Dries DL
Am Heart J; 2004 Nov; 148(5):883-8. PubMed ID: 15523322
[TBL] [Abstract][Full Text] [Related]
43. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study.
Pedersen OD; Brendorp B; Elming H; Pehrson S; Køber L; Torp-Pedersen C
Card Electrophysiol Rev; 2003 Sep; 7(3):220-4. PubMed ID: 14739717
[TBL] [Abstract][Full Text] [Related]
44. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).
Domanski M; Norman J; Pitt B; Haigney M; Hanlon S; Peyster E;
J Am Coll Cardiol; 2003 Aug; 42(4):705-8. PubMed ID: 12932605
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.
Dries DL; Sweitzer NK; Drazner MH; Stevenson LW; Gersh BJ
J Am Coll Cardiol; 2001 Aug; 38(2):421-8. PubMed ID: 11499733
[TBL] [Abstract][Full Text] [Related]
46. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction.
Suskin N; Sheth T; Negassa A; Yusuf S
J Am Coll Cardiol; 2001 May; 37(6):1677-82. PubMed ID: 11345383
[TBL] [Abstract][Full Text] [Related]
47. A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction.
Abdulla J; Abildstrom SZ; Christensen E; Kober L; Torp-Pedersen C
Eur J Heart Fail; 2004 Dec; 6(7):927-35. PubMed ID: 15556055
[TBL] [Abstract][Full Text] [Related]
48. New-onset atrial fibrillation predicts heart failure progression.
Aleong RG; Sauer WH; Davis G; Bristow MR
Am J Med; 2014 Oct; 127(10):963-71. PubMed ID: 24931393
[TBL] [Abstract][Full Text] [Related]
49. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
Carson PE; Johnson GR; Dunkman WB; Fletcher RD; Farrell L; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI102-10. PubMed ID: 8500233
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure.
Crijns HJ; Tjeerdsma G; de Kam PJ; Boomsma F; van Gelder IC; van den Berg MP; van Veldhuisen DJ
Eur Heart J; 2000 Aug; 21(15):1238-45. PubMed ID: 10924313
[TBL] [Abstract][Full Text] [Related]
51. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis.
Anselmino M; Matta M; D'Ascenzo F; Bunch TJ; Schilling RJ; Hunter RJ; Pappone C; Neumann T; Noelker G; Fiala M; Bertaglia E; Frontera A; Duncan E; Nalliah C; Jais P; Weerasooriya R; Kalman JM; Gaita F
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1011-8. PubMed ID: 25262686
[TBL] [Abstract][Full Text] [Related]
52. Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction.
Bunch TJ; May HT; Bair TL; Jacobs V; Crandall BG; Cutler M; Weiss JP; Mallender C; Osborn JS; Anderson JL; Day JD
J Cardiovasc Electrophysiol; 2015 Apr; 26(4):363-370. PubMed ID: 25534572
[TBL] [Abstract][Full Text] [Related]
53. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
54. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction.
Kostis JB
Am J Hypertens; 1995 Sep; 8(9):909-14. PubMed ID: 8541006
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Santos AB; Roca GQ; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Fang JC; Zile MR; Pitt B; Solomon SD; Shah AM
Circ Heart Fail; 2016 Apr; 9(4):e002763. PubMed ID: 27056882
[TBL] [Abstract][Full Text] [Related]
56. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
Szucs TD; Goedde M; Berger K; Kiowski W
Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
[TBL] [Abstract][Full Text] [Related]
57. Ischemic Heart Disease Modifies the Association of Atrial Fibrillation With Mortality in Heart Failure With Reduced Ejection Fraction.
Mercer BN; Koshy A; Drozd M; Walker AMN; Patel PA; Kearney L; Gierula J; Paton MF; Lowry JE; Kearney MT; Cubbon RM; Witte KK
J Am Heart Assoc; 2018 Oct; 7(20):e009770. PubMed ID: 30371286
[TBL] [Abstract][Full Text] [Related]
58. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.
Cooper HA; Dries DL; Davis CE; Shen YL; Domanski MJ
Circulation; 1999 Sep; 100(12):1311-5. PubMed ID: 10491376
[TBL] [Abstract][Full Text] [Related]
59. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation.
Fauchier L; Villejoubert O; Clementy N; Bernard A; Pierre B; Angoulvant D; Ivanes F; Babuty D; Lip GY
Am J Med; 2016 Dec; 129(12):1278-1287. PubMed ID: 27476087
[TBL] [Abstract][Full Text] [Related]
60. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
Konstam MA; Rousseau MF; Kronenberg MW; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D
Circulation; 1992 Aug; 86(2):431-8. PubMed ID: 1638712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
